15.05.2024 16:00:14 - *DJ Novartis highlights pioneering innovation in CML with data from Scemblix(R) Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA

(MORE TO FOLLOW) Dow Jones Newswires

May 15, 2024 10:00 ET (14:00 GMT)
Name WKN Börse Kurs Datum/Zeit Diff. Diff. % Geld Brief Erster Schluss
NOVARTIS NAM. SF 0,49 904278 Hamburg 0,000 25.06.24 21:23:15 ±0,000 ±0,00% 0,000 0,000 0,000 80,190
Novartis AG 907122 NYSE 107,200 25.06.24 21:08:12 +0,250 +0,23% 107,190 107,210 107,220 106,950

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH